Literature DB >> 2426020

Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin.

S Barnass, J Mace, J Steele, P Torres, B Gervasoni, R Ravioli, J Terencio, G A Rook, M F Waters.   

Abstract

Peripheral blood mononuclear cells from 97 predominantly lepromatous leprosy patients and 11 control subjects were tested in a lymphoproliferative assay for response to Mycobacterium leprae (whole and sonicated), and sonicated M. vaccae, M. tuberculosis, and M. scrofulaceum, in the presence and absence of three types of interleukin 2 (IL-2) (crude, purified, and recombinant). IL-2 enhanced the response to sonicated M. tuberculosis and M. leprae organisms more often in patients than in control subjects, but not significantly so and only in a minority of patients. This effect was significantly more common (though still only found in a minority of 46%) using M. leprae organisms as antigen, than when using sonicates of M. leprae (19%) or M. vaccae (19%). However it was nearly as frequent using sonicated M. tuberculosis, or M. scrofulaceum. Thus in only nine patients was the effect specific to M. leprae. Enhancement by IL-2 could not be related to the type of IL-2 used, the dose of antigen, or the amount of endogenous IL-2 released by the cells tested. Similarly it was not related to the extent to which IL-2 caused increased background proliferation in control wells, which occurred to an equal extent using cells from control subjects, nor was it related to the extent of antigen-driven proliferation. The data have also been analysed in relation to duration of disease (50 years to a few weeks) and ethnic origin. No correlations have been revealed. Thus enhancement by IL-2 of the lymphoproliferative response to mycobacterial antigens does occur using cells from lepromatous leprosy patients, but it is found in a minority of patients, it is not specific to M. leprae, and can occur with cells from normal donors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426020      PMCID: PMC1542157     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Unresponsiveness to Mycobacterium leprae in lepromatous leprosy in vitro: reversible or not?

Authors:  T H Ottenhoff; D G Elferink; R R de Vries
Journal:  Int J Lepr Other Mycobact Dis       Date:  1984-09

Review 2.  Molecular characterization of interleukin 2.

Authors:  S Gillis; D Y Mochizuki; P J Conlon; S H Hefeneider; C A Ramthun; A E Gillis; M B Frank; C S Henney; J D Watson
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

3.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

4.  Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to Mycobacterium leprae.

Authors:  A Haregewoin; A S Mustafa; I Helle; M F Waters; D L Leiker; T Godal
Journal:  Immunol Rev       Date:  1984-08       Impact factor: 12.988

5.  Multiple skin testing in leprosy.

Authors:  R C Paul; J L Stanford; J W Carswell
Journal:  J Hyg (Lond)       Date:  1975-08

6.  Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis.

Authors:  P Emery; G S Panayi; A M Nouri
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

7.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

8.  T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy.

Authors:  A Haregewoin; T Godal; A S Mustafa; A Belehu; T Yemaneberhan
Journal:  Nature       Date:  1983-05-26       Impact factor: 49.962

9.  Evidence for the presence of M. leprae reactive T lymphocytes in patients with lepromatous leprosy.

Authors:  I Nath; M Sathish; T Jayaraman; L K Bhutani; A K Sharma
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  An analysis of in vitro T cell responsiveness in lepromatous leprosy.

Authors:  G Kaplan; D E Weinstein; R M Steinman; W R Levis; U Elvers; M E Patarroyo; Z A Cohn
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more
  6 in total

1.  Limiting dilution analysis of T cell unresponsiveness to mycobacteria in advanced disseminated tuberculosis.

Authors:  M S Gilardini Montani; F Del Gallo; G Lombardi; P Del Porto; E Piccolella; F Arienzo; V Colizzi
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

Review 2.  Progress in the immunology of the mycobacterioses.

Authors:  G A Rook
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

3.  Accessory cell heterogeneity in lepromatous leprosy; dendritic cells and not monocytes support T cell responses.

Authors:  A Mittal; R S Mishra; I Nath
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

4.  Defective cell mediated immunity in sarcoidosis: effect of interleukin-2.

Authors:  D J Lyons; L Gao; E B Mitchell; D N Mitchell
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

5.  Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice.

Authors:  A Jeevan; G L Asherson
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

6.  Correlation between macrophage activation and bactericidal function and Mycobacterium leprae antigen presentation in macrophages of leprosy patients and normal individuals.

Authors:  S D Desai; T J Birdi; N H Antia
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.